Login to Your Account

DeveloGen, BI Partner in €244M Diabetes Pact

By Cormac Sheridan

Wednesday, May 20, 2009

No Abstract


BioWorld International Correspondent

DeveloGen AG is getting an up-front payment of €7 million (US$9.52 million) and could earn as much as €237 million more in milestone payments from Boehringer Ingelheim GmbH, in return for a novel drug target for Type II diabetes and other metabolic diseases, a series of chemical leads and associated intellectual property and know-how.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription